 VICTORIA, British Columbia--BUSINESS WIRE--- IPA POLYTOPE--IMMUNOPRECISE ANTIBODIES LTD. the Company or IPA NASDAQ: IPA TSX VENTURE: IPA a leader in full-service, therapeutic antibody discovery and development, today announced that the over-allotment option the Option granted in connection with its previously announced bought deal offering of 1,616,293 common shares the Common Shares in the capital of the Company the Offering, has been fully exercised. H.C. Wainwright Co. has purc 